Back

Oxidative Stress-Induced Immunogenic Cell Death Enhances Whole-Cell Vaccine Efficacy in a Syngeneic Pancreatic Cancer Model

Katoueezadeh, M.; Thinakaran, Y.; Laein, M. H.; Iyappan, R.; Ngan, S. C.; Baker, J.; Patel, R.; Kalailingam, P.; Macpherson, R. E. K.; Klentrou, P.; Tsiani, E. L.; Low, J. K.; McCarthy, N. E. K.; Sze, S. K.

2026-02-11 cancer biology
10.64898/2026.02.09.704828 bioRxiv
Show abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer, with limited therapeutic options and extremely high mortality rates. While immune checkpoint blockade (ICB) therapy is effective in many types of human cancers, responses in PDAC patients remain poor, partly due to the weak immunogenicity of PDAC tumors. We hypothesized that a whole-cell PDAC vaccine could improve anti-tumor responses if optimized to expose a more stimulatory repertoire of tumor antigens. To test this, we used murine Panc02 pancreatic cancer cells to screen several stress-inducing treatments (UV, hypoxia, heat shock, and hydrogen peroxide [H2O2]), among which low-dose oxidative stress (0.05% H2O2 for 2h) was identified as the optimal inducer of immunogenic cell death (including increased surface calreticulin, ERp57 exposure, HMGB1 release and MHC class I expression). We then prepared a whole-cell vaccine of fixed H2O2-treated Panc02 cells, which induced robust tumor-specific immunity in C57BL/6 mice bearing syngeneic Panc02 tumors. Vaccine-treated mice displayed a significant increase in tumor-reactive IFN{gamma}+ T cells, as well as extensive tumor infiltration by CD4 + and CD8 + T cells and NCR1+ NK cells. When used prophylactically, the vaccine significantly delayed tumor growth and extended survival, whereas therapeutic application markedly slowed tumor progression. Importantly, combining the whole-cell Panc02 vaccine with anti-PD-1 therapy induced complete tumor regression in a subset of animals. Together, these data demonstrate that controlled oxidative stress can convert autologous tumor cells into an effective whole-cell vaccine without the need for genetic modification or prior neoantigen identification, offering a scalable strategy for personalized immunotherapy in PDAC. STATEMENT OF SIGNIFICANCEThis study demonstrated that oxidative stress-induced immunogenic cell death reprograms pancreatic tumor cells to induce danger signaling and enhance antigen presentation, thereby promoting immune infiltration and sensitizing tumors to PD-1 blockade.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.1%
38.1%
2
Molecular Cancer Therapeutics
33 papers in training set
Top 0.1%
4.9%
3
Cancer Cell
38 papers in training set
Top 0.3%
4.3%
4
JCI Insight
241 papers in training set
Top 1%
4.0%
50% of probability mass above
5
eLife
5422 papers in training set
Top 31%
2.8%
6
Cell Reports Medicine
140 papers in training set
Top 2%
2.8%
7
Cancer Research Communications
46 papers in training set
Top 0.2%
2.6%
8
Cancer Immunology, Immunotherapy
11 papers in training set
Top 0.1%
2.4%
9
Gastroenterology
40 papers in training set
Top 0.9%
1.8%
10
Cancer Immunology Research
34 papers in training set
Top 0.3%
1.7%
11
Clinical Cancer Research
58 papers in training set
Top 1.0%
1.7%
12
Nature Communications
4913 papers in training set
Top 51%
1.7%
13
Molecular Therapy
71 papers in training set
Top 2%
1.5%
14
EMBO Molecular Medicine
85 papers in training set
Top 2%
1.3%
15
Scientific Reports
3102 papers in training set
Top 66%
1.2%
16
Cancer Research
116 papers in training set
Top 3%
1.2%
17
Cell Reports
1338 papers in training set
Top 28%
1.2%
18
eBioMedicine
130 papers in training set
Top 3%
1.0%
19
Gut
36 papers in training set
Top 0.7%
0.9%
20
Journal of Clinical Investigation
164 papers in training set
Top 6%
0.8%
21
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 44%
0.8%
22
Cell Death & Disease
126 papers in training set
Top 2%
0.8%
23
Nature Cancer
35 papers in training set
Top 1%
0.8%
24
BMC Cancer
52 papers in training set
Top 3%
0.7%
25
Science Advances
1098 papers in training set
Top 31%
0.7%
26
Evolutionary Applications
91 papers in training set
Top 1%
0.7%
27
Science Translational Medicine
111 papers in training set
Top 8%
0.5%
28
Theranostics
33 papers in training set
Top 2%
0.5%